0001209191-23-007912.txt : 20230208
0001209191-23-007912.hdr.sgml : 20230208
20230208192814
ACCESSION NUMBER: 0001209191-23-007912
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230206
FILED AS OF DATE: 20230208
DATE AS OF CHANGE: 20230208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GORMAN KEVIN CHARLES
CENTRAL INDEX KEY: 0001201096
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 23600616
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-06
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001201096
GORMAN KEVIN CHARLES
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
1
1
0
0
Chief Executive Officer
Common Stock
2023-02-06
4
S
0
3040
105.6772
D
468008
D
Common Stock
2023-02-07
4
S
0
3248
102.2985
D
470930
D
Common Stock
2023-02-07
4
S
0
20482
102.4338
D
489322
D
Common Stock
2023-02-08
4
S
0
2274
104.3028
D
491365
D
Sale of 3,040 shares of common stock issued upon vesting of 5,770 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,730) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.64 to $108.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 3,248 shares of common stock issued upon vesting of 6,170 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,922) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.39 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 20,482 shares of common stock issued upon vesting of 38,874 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (18,392) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.03 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.72 to $105.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
/s/ Darin Lippoldt, Attorney-in-Fact
2023-02-08